1.Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries.
Expert Rev Clin Pharmacol. 2015;8(4):449-60.
2. Curtolo E, Micallef B, Szijj JV, Serracino-Inglott A, Borg JJ. An exploratory
study of knowledge, attitudes, practice and barriers towards adverse drug
reaction reporting among healthcare professionals in Malta. Int J Risk Saf Med.
2024;35(3):271-286.
3. Jnaneswar A, Hazarika SJ, Jha K, Vinay S, Kumar G. Knowledge, attitude,
practices, and barriers regarding pharmacovigilance and adverse drug reaction
reporting among medical and dental faculties of the teaching hospitals in
Bhubaneswar City. J Educ Health Promot. 2020 Oct 30;9:282.
4. Gahr M, Connemann BJ, Schönfeldt-Lecuona C, Freudenmann RW,
Stein JM, Hawlik AK. Psychiatrists' and dentists' knowledge and attitudes
regarding adverse drug reactions of psychotropic drugs. Psychiatry Res.
2018 Aug;266:323-327.
5. Chhabra KG, Sharma A, Chhabra C, Reddy JJ, Deolia SG, Mittal Y.
Knowledge, Attitude, and Practices regarding Pharmacovigilance and
Adverse Drug Reaction reporting among Dental Students in a Teaching
Hospital, Jodhpur, India: A Cross-sectional Study. J Contemp Dent Pract.
2017 Oct 1;18(10):964-969.
6. Khan SA, Goyal C, Tonpay SD. A study of knowledge, attitudes, and
practice of dental doctors about adverse drug reaction reporting in a teaching
hospital in India. Perspect Clin Res. 2015 Jul-Sep;6(3):144-9.
7. Karl EH, Curro FA. Medical Histories: A Case Report of
Pharmacovigilance in Supporting Dentists and Participation in a Drug-
Safety Program. Clin Adv Periodontics. 2013 Feb;3(1):40-43.
8. Dincă FI, Dimitriu BA, Săndulescu O, Sîrbu VD, Săndulescu M.
Knowledge, Attitudes, and Practices of Dental Students from Romania
Regarding Self-Perceived Risk and Prevention of Infectious Diseases. Dent
J (Basel). 2024 Apr 10;12(4):97.
9. Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P,
Haramburu F; EMIR Study Group on behalf of the French network of
pharmacovigilance centres. Incidence of hospital admissions due to adverse
drug reactions in France: the EMIR study. Fundam Clin Pharmacol. 2015
Feb;29(1):106-11.
10. Opadeyi AO, Fourrier-Réglat A, Isah AO. KNOWLEDGE, ATTITUDE
AND PRACTICE OF HEALTH CARE PROFESSIONALS REGARDING
PHARMACOVIGILANCE IN SOUTH-SOUTH NIGERIA. Kanem Journal of
Medical Sciences 2021;15(1): 54-64.
11. Oumar AA, Sangare M, Fofana S, Cissoko Y, Diallo D, Maiga M et al.
Chapter 39 - Drug safety in Mali. Editors Yaser Al-Worafi Drug Safety in
Developing Countries Achievements and Challenges. Academic Press 2020,
Pages 557-568. ISBN 978-0-12-819837-7 https://doi.org/10.1016/B978-0-12-
819837-7.00039-X
12.Soukho-Kaya A, Minta DK, Diarra MT et al. Undesirable effects of
medicine in the Internal Medicine Service of the University Hospital Center du
Point G [in French] Mali Med . 2010;25(3):10–14.
13. Khan Z, Karatas Y, Hamid SM. Evaluation of health care
professionals' knowledge, attitudes, practices and barriers
to pharmacovigilance and adverse drug reaction reporting: A cross-sectional
multicentral study. PLoS One. 2023 May 24;18(5):e0285811
1
/
2
100%